New Zealand medicines with clinical-trial evidence for a new indication

34 of the 461 medicines with a NZTxGNN report have a TxGNN-predicted new indication graded at evidence level L1 or L2 (9 at L1, 25 at L2), meaning clinical-trial evidence (randomised trials, Phase 2–3 trials or systematic reviews) was found for it.

The medicines come from the Pharmac Community Pharmaceutical Schedule (a funding schedule, not a licence register: Medsafe licence status is not included); the list reflects the drug reports as last updated on 2026-11-20.

Trial evidence for a predicted indication is not proof of efficacy. Every candidate below still requires clinical validation and regulatory review before any clinical use.

Medicines with trial evidence (L1–L2)

DrugPredicted new indicationEvidence levelRegistered trials cited (NCT)
Acetylcysteinethrombotic diseaseL17
Bendamustinemantle cell lymphomaL110
Bupropionattention deficit-hyperactivity disorderL16
Busulfanmyelodysplastic syndromeL110
ClomipramineAnxiety disorderL18
DapsonePneumocystosisL110
DoxorubicinEwing sarcomaL111
KetamineHeadache disorderL1 (with caveat)9
TacrolimusSeborrheic dermatitisL13
AtorvastatinHIV infectious diseaseL210
Citalopramobsessive-compulsive disorderL24
ClozapineManic bipolar affective disorderL21
DiazepamInsomnia (disease)L20
EverolimusLiposarcomaL23
GoserelinAmenorrhea (disease)L21
HydrocortisoneAlopecia areataL21
Hydrocortisone AcetateAlopecia areataL21
LedipasvirHepatitis B virus infectionL25
LenalidomideMyeloid leukemiaL2 (with caveat)11
LevonorgestrelAcne (disease)L20
Mefenamic AcidHeadache disorderL2 (with caveat)0
MoclobemideAgoraphobiaL20
MontelukastBronchitisL210
Mycophenolate MofetilHIV infectious diseaseL2 (with caveat)4
NortriptylineAttention deficit-hyperactivity disorderL20
OxaliplatinMalignant pleural mesotheliomaL2 (with caveat)3
PazopanibLiposarcomaL2 (with caveat)8
PimecrolimusSeborrheic dermatitisL22
PrednisoloneAlopecia areataL20
SucralfateDuodenogastric refluxL20
SunitinibLiposarcomaL22
TocilizumabAnkylosing spondylitisL24
UstekinumabDermatitisL26
VinorelbineEwing sarcomaL23

How to read this list

  • Evidence level follows the site's criteria: L1 = Multiple Phase 3 RCTs / systematic reviews; L2 = Single RCT or multiple Phase 2 trials. "(with caveat)" means the drug report qualifies the grade; read the note in the report before relying on it.
  • Predicted new indication is the main prediction shown in each drug report. Indications and contraindications already recorded in the TxGNN knowledge graph are excluded, but some predictions may still overlap an established use; the report explains this where it applies.
  • Registered trials cited counts the ClinicalTrials.gov (NCT) numbers cited in the drug report. Reports cite a selection of the trials found; 0 means the report cites no registered trial, and its literature evidence section shows the basis for the grade.
  • For all levels and the full method, see High Evidence (L1-L2), All Drugs and the methodology.

Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.

Reviewed by: 藥提醒科技有限公司 (yao.care)